Drew Moghanaki, Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, shared Evan Thomas’s, Chief Technology Officer at JointGLOW, Executive Chair at Renaissance Institute of Precision Oncology and Radiosurgery, post on LinkedIn, adding:
“There aren’t any that are reliable. The cystectomy remains a preferred upfront local therapy only because of historical bullying and persistent gaslighting in discussions about non-surgical alternatives.”
Quoting Evan Thomas’s post:
“In your mind, what data establishes radical cystectomy as the definitive standard of care that TMT therapy needs to prove itself over?”
Other articles about bladder cancer and cystectomy on OncoDaily.